Am J Hematol

1. LUNNING MA, Wang HL, Hu ZH, Locke FL, et al
   Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy.
   Am J Hematol. 2024 Mar 19. doi: 10.1002/ajh.27283.
   

   >> Share

   
   
2. JABBOUR E, Zugmaier G, Agrawal V, Martinez-Sanchez P, et al
   Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
   Am J Hematol. 2024 Feb 5. doi: 10.1002/ajh.27227.
   

   >> Share

   
   

   
   Am J Surg Pathol

3. SAKA M, Fujimoto M, Mizoguchi K, Tsujimura M, et al
   Insulin-like Growth Factor II mRNA-binding Protein 3 is a Highly Sensitive Marker for Intravascular Large B-cell Lymphoma: Immunohistochemical Analysis of 152 Pathology Specimens From 88 Patients.
   Am J Surg Pathol. 2024 Mar 18. doi: 10.1097/PAS.0000000000002214.
   

   >> Share

   
   

   
   Blood

4. STEIDL C, Stevenson FK
   Introduction to a review series on the influence of the tumor microenvironment on the pathogenesis of B-cell lymphomas.
   Blood. 2024;143:1057-1058.
   

   >> Share

   
   
5. RYAN CE, Armand P, LaCasce AS
   Frontline Treatment of Mantle Cell Lymphoma.
   Blood. 2024 Mar 18:blood.2023022352. doi: 10.1182/blood.2023022352.
   

   >> Share

   
   

   
   Cancer

6. NIERENGARTEN MB
   Golidocitinib favorable for relapsed/refractory T-cell lymphoma.
   Cancer. 2024;130:1191-1192.
   

   >> Share

   
   
7. LI A, Yi H, Deng S, Ruan M, et al
   The genetic landscape of histologically transformed marginal zone lymphomas.
   Cancer. 2024;130:1246-1256.
   

   >> Share

   
   

   
   Haematologica

8. TOLLEY ER, Lewinter C, Pedersen LM, Nielsen TH, et al
   Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: a systematic review and meta-analysis.
   Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284281.
   

   >> Share

   
   
9. ZHU ML, Drill E, Joffe E, Salles G, et al
   Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
   Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284565.
   

   >> Share

   
   
10. IANNITTO E, Ferrero S, Bommier C, Drandi D, et al
    Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
    Haematologica. 2024 Mar 14. doi: 10.3324/haematol.2023.284109.
    

    >> Share

    
    
11. WIGHT J, Blombery P, Lickiss J, Burgess M, et al
    Systemic diffuse large B-cell lymphoma involving the central nervous system have high rates of defective antigen presentation and immune surveillance.
    Haematologica. 2024 Mar 21. doi: 10.3324/haematol.2023.284600.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

12. PARIKH RR, Milgrom SA, Campbell BA
    Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
    Int J Radiat Oncol Biol Phys. 2024;118:1152-1158.
    

    >> Share

    
    

    
    J Am Acad Dermatol

13. BANNER L, Rohan TZ, Zachian R, Gross T, et al
    Increased incidence of thyroid, renal, lung, melanoma, bladder, and prostate cancers after diagnosis of primary cutaneous B-cell lymphoma: A SEER database analysis.
    J Am Acad Dermatol. 2024 Mar 19:S0190-9622(24)00505.
    

    >> Share

    
    
14. CHEN J, Martinez A, Shinohara MM
    Risk of Systemic Lymphoma in Patients with Cutaneous CD30+ Lymphoproliferative Disorders: A Single Center Retrospective Cohort Analysis.
    J Am Acad Dermatol. 2024 Mar 13:S0190-9622(24)00489.
    

    >> Share

    
    

    
    Leuk Lymphoma

15. RYU TIGER YK, Jain S, Barta SK, Tolu S, et al
    Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 22:1-10. doi: 10.1080/10428194.2024.2329996.
    

    >> Share

    
    
16. TZIONI MM, Clipson A, Chen Z, Cucco F, et al
    Progressive TP53 inactivation in an aggressive splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 22:1-5. doi: 10.1080/10428194.2024.2332508.
    

    >> Share

    
    
17. GAO LR, Wang X, Wu Y, Feng XL, et al
    Treatment outcome, toxicity, and quality of life of patients with bronchus-associated lymphoid tissue lymphoma.
    Leuk Lymphoma. 2024 Mar 20:1-12. doi: 10.1080/10428194.2024.2329328.
    

    >> Share

    
    
18. ITCHAKI G, Jarhovsky O, Castillo JJ, Hassan H, et al
    Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review.
    Leuk Lymphoma. 2024 Mar 19:1-7. doi: 10.1080/10428194.2024.2332499.
    

    >> Share

    
    
19. LI L, Yang W, Pan Y, Ye R, et al
    Chidamide enhances T-cell-mediated anti-tumor immune function by inhibiting NOTCH1/NFATC1 signaling pathway in ABC-type diffuse large B-cell lymphoma.
    Leuk Lymphoma. 2024 Mar 18:1-16. doi: 10.1080/10428194.2024.2328227.
    

    >> Share

    
    

    
    Leukemia

20. GAO LR, Li X, Wang X, Liang Y, et al
    Treatment and survival for patients with localized primary ocular adnexal extranodal marginal zone lymphoma.
    Leukemia. 2024 Mar 19. doi: 10.1038/s41375-024-02227.
    

    >> Share

    
    

    
    N Engl J Med

21. VIPLER B
    "What's Lymphoma?" - Risks Posed by Immediate Release of Test Results to Patients.
    N Engl J Med. 2024;390:1064-1066.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share